Have a personal or library account? Click to login
Piperazine sulfonamides as DPP-IV inhibitors: Synthesis, induced-fit docking and in vitro biological evaluation Cover

Piperazine sulfonamides as DPP-IV inhibitors: Synthesis, induced-fit docking and in vitro biological evaluation

Acta Pharmaceutica
Volume 71 (2021): Issue 4 (December 2021)
By: Reema Abu Khalaf,  Ebtisam Alwarafi and  Dima Sabbah  
Open Access
|Apr 2021

Authors

Reema Abu Khalaf

reema.abukhalaf@zuj.edu.jo

Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan

Ebtisam Alwarafi

Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan

Dima Sabbah

Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan
DOI: https://doi.org/10.2478/acph-2021-0034 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 631 - 643
Accepted on: Oct 20, 2020
Published on: Apr 3, 2021
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
piperazine sulfonamide,
dipeptidyl peptidase-IV inhibitor,
diabetes mellitus,
induced-fit docking
Related subjects:
Pharmacy,
Pharmacy, other

© 2021 Reema Abu Khalaf, Ebtisam Alwarafi, Dima Sabbah, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 71 (2021): Issue 4 (December 2021)Next article